Global Erythromycin Market By Product Type (Erythromycin Thiocyanate, Azithromycin, Clarithromycin, Roxithromycin), By End-Use (Human Medication, Veterinary Medication) and By Region - Global Forecast 2030
-
17659
-
April 2023
-
256
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
“Global Erythromycin Market” is the title of a recently published market report compiled by MarketResearch.Biz. The report contains information and data, and inputs from both primary and secondary data sources, that have been verified and validated by experts in the target market. The report presents a thorough study of revenues, historical data, and information, key developments, and strategies by major players that offer vital insights and perspectives in to various scenarios market. Besides critical data and related information, the report includes key trends (both present and future), factors that are driving market growth, factors that are or could be potential restraints to market growth, as well as opportunities that can be leveraged for potential revenue generation in untapped regions and countries. It also covers threats or challenges for existing as well as new entrants in the market. The global erythromycin market has been segmented on the basis of product type, end-use, as well as regions and countries.
The Global Erythromycin Market was valued at UЅD $15,030.8 Мn in 2020, and is projected to achieve a valuation of UЅD $8,194.9 Мn by 2030, at a САGR of 5.5%.
Overview:
Erythromycin is an antibiotic used for the treatment of numerous bacterial infections, including, skin infections, respiratory tract infections, syphilis, pelvic inflammatory disease, chlamydia, etc.
Dynamics:
The increasing prevalence of contagious bacterial infections, especially in warmer, tropical regions, is leading to the greater demand for effective antibiotics, thereby boosting opportunities for market growth of this global industry in the foreseeable future. Moreover, the listing of erythromycin by the WHO as a generic, essential form of medication, has resulted in this product becoming more inexpensive. This is also a factor that is slated to fuel the revenue growth of the global erythromycin market in the years to come.
In light of the recent COVID-19 outbreak, the operations of numerous industries have either been temporarily halted or are functioning with a minimal workforce due to enforced lockdowns and imposed restrictions by respective governing bodies. The global erythromycin market is no different, and this factor initially did have a negative impact on the revenue growth of this industry. However, as erythromycin can be used to treat specific symptoms of the coronavirus, the demand for this product has exponentially risen in recent months. This is a factor that is expected to have a profound impact on the revenue growth of the global erythromycin market in the near future.
Nonetheless, the increasing capability of erythromycin as an effective form of treatment and prevention for a wide range of infections such as skin infections, STDs, eye infections, etc. Owing to this major benefit, the demand for these products is expected to increase exponentially over the forecast period, boosting the revenue growth of this global market in the process.
Segmentation of the Global Erythromycin Market is as follows:
In terms of product type, the azithromycin segment accounted for the maximum number of revenue shares of the global erythromycin market in 2020, and is expected to index the highest CAGR over the forecast period. The erythromycin thiocyanate segment is also anticipated to index a high CAGR over the next 10 years.
With regards to end-use, the human medication segment accounted for the highest number of revenue shares of the global erythromycin market in 2020, and is anticipated to continue doing so over the next decade. The veterinary medication segment is also indicative of registering a high CAGR over the forecast period.
Regional Segmentation and Analysis:
North America accounted for the maximum number of revenue shares of the global erythromycin market in 2020, and is indicative of remaining this industry’s front-runner over the next decade. However, the markets in the Asia Pacific region are anticipated to register the highest CAGR over the course of the forecast period.
Segmentation of the Global Erythromycin Market:
Segmentation by Product Type:
- Erythromycin Thiocyanate
- Azithromycin
- Clarithromycin
- Roxithromycin
- Others
Segmentation by End-Use:
- Human Medication
- Veterinary Medication
Segmentation by Regions:
- North America
- Europe
- APAC
- Latin America
- MEA
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
-
- Pfizer Inc.
- AbbVie Inc.
- Abbott Laboratories
- Ercros S.A.
- Genesis Pharmaceutical Inc. (Pierre Fabre Dermo-Cosmetique The US, Inc.)
- Akorn Inc.
- Alembic Pharmaceuticals Ltd.
- Ani Pharmaceuticals Inc.
- Ningxia Qiyuan Pharmaceutical Co. Ltd.
- Teligent Inc.
- Anuh Pharma Limited